KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenet Healthcare (THC) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Tenet Healthcare (THC) over the last 17 years, with Q4 2025 value amounting to $25.0 million.

  • Tenet Healthcare's Share-based Compensation rose 6666.67% to $25.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.0 million, marking a year-over-year increase of 5522.39%. This contributed to the annual value of $104.0 million for FY2025, which is 5522.39% up from last year.
  • Tenet Healthcare's Share-based Compensation amounted to $25.0 million in Q4 2025, which was up 6666.67% from $38.0 million recorded in Q3 2025.
  • Tenet Healthcare's 5-year Share-based Compensation high stood at $38.0 million for Q3 2025, and its period low was $9.0 million during Q4 2022.
  • For the 5-year period, Tenet Healthcare's Share-based Compensation averaged around $17.4 million, with its median value being $16.0 million (2021).
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 3076.92% in 2022, then soared by 13750.0% in 2025.
  • Quarter analysis of 5 years shows Tenet Healthcare's Share-based Compensation stood at $13.0 million in 2021, then crashed by 30.77% to $9.0 million in 2022, then surged by 100.0% to $18.0 million in 2023, then fell by 16.67% to $15.0 million in 2024, then soared by 66.67% to $25.0 million in 2025.
  • Its Share-based Compensation stands at $25.0 million for Q4 2025, versus $38.0 million for Q3 2025 and $20.0 million for Q2 2025.